Press Room
-
04/25/2012
Increasingly Complex World of Early Drug Development
Early-drug-development.pdf (145.44 KB)
Simbec tailors its Phase I & IIa services to meet the needs of our customers, having the flexibility to respond to the ever-changing requirements.
In the past few years we have responded to the “kill it early” philosophy expressed by many of our customers. We are increasingly focused on obtaining early indications of efficacy and proof of concept (POC) on top of the conventional safety and tolerability concerns that facilitate critical GO/NO GO decisions. These POC results allow for crucial decisions on whether to progress new medicinal products into full development. -
03/29/2012
AB SCIEX QTRAP® 5500 LC/MS/MS System
AB-Sciex-QTrap.pdf (623.93 KB)
Selecting Algorithme Pharma as your CRO of choice for bioanalysis now has an added advantage: the analysis using AB SCIEX QTRAP® 5500 LC/MS/MS System and the highly selective MRM3.
-
02/22/2012
Ligand Binding Assays
Bulletin-Ligand-binding.pdf (134.09 KB)
We assess the PK and Immunogenicity profile of our biologics and biosimilars
Novel biologics license applications (BLA) have accounted for almost 25% of all FDA approved drugs in recent years. Robust and customizable bioanalytical methods are the backbone of getting valid pharmacokinetic and immunogenicity data throughout preclinical and clinical development phases of biologics and follow-on biologic products.
At Algorithme Pharma, our skilled scientists can develop methods from commercially available kits or customized de novo ELISA in different formats (e.g. competitive direct, indirect and sandwich) for determining therapeutic proteins, monoclonal antibodies, peptides or biomarkers in various biological matrices. For oligonucleotides, ELISA methods coupled with hybridization techniques are applied for quantitation.
-
02/08/2012
Critical Outcome Technologies Inc. announced today it has engaged Algorithme Pharma Inc.
120208_COTI_COTI-2_detection.pdf (105.1 KB)
London, Ontario: Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)
announced today that it has engaged Algorithme Pharma Inc. (Algorithme) of Montreal, Canada, an
internationally recognized contract research organization, to develop and validate the final quantitative
method to be used for preclinical and Phase 1 studies for COTI‐2. -
02/08/2012
Sensitivity and Speed: Bioanalysis Development at Algorithme Pharma
We are proud to offer next generation technology to address increasing challenges of metabolite identification and protein and peptide quantitation. In working to best address the needs of our clients, we are now conducting analysis using AB Sciex QTrap 5500 and the highly selective MRM3.
-
11/03/2011
RedHill Biopharma engages with Algorithme Pharma
RedHill Biopharma is preparing for an advanced clinical trial with RHB-102, a drug for the prevention of nausea and vomiting in cancer patients undergoing chemotherapy and radiotherapy.
The company reported an engagement with a Canadian CRO, Algorithme Pharma, for the execution of the RHB-102 clinical trial.
The drug market for Serotonin Receptor Inhibitors is estimated at $700 million in the US alone.
-
09/13/2011
Thrasos Innovation, Inc.
Thrasos Press Release September13 2011.pdf (116 KB)
MONTREAL, September 13, 2011 – Thrasos Innovation, Inc. today announced that it has initiated a Phase 1 clinical trial to study the safety and tolerability of THR-184, which the Company is developing for the treatment of Acute Kidney Injury (AKI) post-surgery. The Phase 1 study is being conducted by Algorithme Pharma of Laval, Quebec, Canada.
-
04/08/2011
Algorithme Pharma announces key clinic appointments
News release - Key clinic appointments.pdf (75.66 KB)
Laval, Friday, April 8, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointments of Ingrid Holmes as Senior Director - Clinical Operations , Matthew Logan as Associate Director - Clinical Operations and Pasquale (Patrick) Omobono as Senior Manager - Clinical Operations.
-
03/21/2011
Algorithme Pharma secures support from Investissement Québec
LAVAL, QC, March 21, 2011 - Algorithme Pharma Inc. (the "Company"), a Canadian clinical contract research organization, with facilities in Laval Québec, Montréal Québec, and through its sister company Simbec Research Limited in Merthyr Tydfil UK, today announced having secured the support of Investissement Québec in the form of a loan, which combined with new equity injection from shareholders of the Company and new credit facility arrangements with the actual principal lenders will allow the company to execute on its strategic plan aiming at growing and diversifying the business.
-
03/07/2011
Algorithme Pharma announce Dr. Robert Massé as Vice President – Large Molecule Bioanalysis.
News Release 03/2011 (100.52 KB)
Algorithme Pharma announces another key strategic appointment.
Laval, Monday, March 7, 2011 – Chris Perkin, President and Chief Executive Officer, is pleased to announce the appointment of Dr. Robert Massé as Vice President – Large Molecule Bioanalysis.
